Panelists discuss how belumosudil is particularly effective for patients with lung involvement due to its antifibrotic mechanism.

Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former ...

Sanofi & Regeneron announce itepekimab meet the primary endpoint in one of two COPD phase 3 studies: Paris Saturday, May 31, 2025, 10:00 Hrs [IST] The AERIFY-1 phase 3 study evalu ...

Discover surprising risk factors for type 2 diabetes beyond diet and weight. Learn about hidden triggers that could increase ...

If you or someone you know has chronic asthma do read this article to know how biologics can potentially help in treating the condition ...

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers rega ...

A range of environmental factors — including chronic or severe stress ... treatments for alopecia universalis are topical and systemic steroids, immunosuppressive agents, and Janus kinase ...

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically me ...

About itepekimab Itepekimab is a fully human monoclonal antibody that binds to and inhibits interleukin-33 (IL33), an initiator and amplifier of broad inflammation in COPD. IL33 is thought to be ...

Kyleigh MacGregor plans her life five years at a time. MacGregor has lupus, an incurable disease in which her immune system ...